Influenza B virus infections account for a substantial proportion of cases of influenza annually, with a high morbidity and mortality burden, especially in children (aged 0–18 years). Influenza B virus, on average, accounts for 23% of the annual influe...
In this real-world setting, single-dose tafenoquine was more effective at preventing P vivax recurrence in patients aged at least 16 years who were G6PD normal compared with 7-day primaquine at day 90, while overall efficacy at 180 days was similar. Th...
In this real-world setting, single-dose tafenoquine was more effective at preventing P vivax recurrence in patients aged at least 16 years who were G6PD normal compared with 7-day primaquine at day 90, while overall efficacy at 180 days was similar. Th...
Prime-boost vaccinations can enhance immune responses,1 whereas chronic antigen exposure can cause immune tolerance.2 In humans, the benefits, limitations, and risks of repetitive vaccination remain poorly understood.
Prime-boost vaccinations can enhance immune responses,1 whereas chronic antigen exposure can cause immune tolerance.2 In humans, the benefits, limitations, and risks of repetitive vaccination remain poorly understood.
Plasmodium vivax causes a substantial burden of disease in the Americas, the Horn of Africa, and Asia-Pacific. The parasite forms dormant liver stages (hypnozoites) that reactivate weeks to months after an initial infection causing recurrent episodes o...
Plasmodium vivax causes a substantial burden of disease in the Americas, the Horn of Africa, and Asia-Pacific. The parasite forms dormant liver stages (hypnozoites) that reactivate weeks to months after an initial infection causing recurrent episodes o...
In the fall of 2023, the US Food and Drug Administration (FDA) authorised the use of the updated Moderna (Sept 11), Pfizer-BioNTech (Sept 11), and Novavax (Oct 3) COVID-19 vaccines containing a monovalent component of the XBB.1.5 variant “to provide be...
In the fall of 2023, the US Food and Drug Administration (FDA) authorised the use of the updated Moderna (Sept 11), Pfizer-BioNTech (Sept 11), and Novavax (Oct 3) COVID-19 vaccines containing a monovalent component of the XBB.1.5 variant “to provide be...
Since the public release of ChatGPT in November, 2022, large language models (LLMs) have been shown to offer undeniably impressive utility in medicine and health care. Their shown proficiency in providing antimicrobial advice,1 writing discharge summar...
Wilder-Smith AB, Wilder-Smith A. Determining force of infection for chikungunya to support vaccine policy development. Lancet Infect Dis 2024; published online Feb 8. https://doi.org/10.1016/S1473-3099(24)00062-8—In this Comment, the seventh sentence o...
BCG-Denmark vaccination did not reduce initial QFT Plus conversion risk in Brazilian health-care workers. This finding underscores the need to better understand tuberculosis prevention in populations at high risk.
In 2022, 1·5 million people died of tuberculosis.1 Just one licensed vaccine exists, the live attenuated Mycobacterium bovis Bacille Calmette-Guérin (BCG). BCG protects infants against disseminated disease but most people who have tuberculosis have pul...
Dengue monoclonal antibody was safe and well tolerated. It showed a dose-proportionate increase in pharmacokinetic exposure. These data support further evaluation of dengue monoclonal antibody in patients with dengue for safety and efficacy.
Dengue monoclonal antibody was safe and well tolerated. It showed a dose-proportionate increase in pharmacokinetic exposure. These data support further evaluation of dengue monoclonal antibody in patients with dengue for safety and efficacy.
Malaria, primarily caused by Plasmodium falciparum, has witnessed a resurgence in some countries since 2019, highlighting the need for effective vaccines. In 2021, WHO recommended the RTS,S/AS01 vaccine (GSK Vaccines, Rixensart, Belgium), the first app...